Medidata Solutions (MDSO) Upgraded by ValuEngine to Buy

ValuEngine upgraded shares of Medidata Solutions (NASDAQ:MDSO) from a hold rating to a buy rating in a research note issued to investors on Friday morning.

Other equities analysts also recently issued research reports about the company. Deutsche Bank boosted their target price on Medidata Solutions from $78.00 to $85.00 and gave the stock a buy rating in a research note on Thursday, May 31st. Dougherty & Co restated a buy rating and issued a $89.00 target price (up previously from $79.00) on shares of Medidata Solutions in a research note on Thursday, May 10th. BidaskClub upgraded Medidata Solutions from a hold rating to a buy rating in a research note on Friday, May 4th. Deutsche Bank boosted their target price on Medidata Solutions from $85.00 to $90.00 and gave the stock a buy rating in a research note on Wednesday, June 13th. Finally, Needham & Company LLC boosted their target price on Medidata Solutions from $80.00 to $90.00 and gave the stock a buy rating in a research note on Wednesday, June 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $87.62.

Shares of NASDAQ MDSO opened at $82.40 on Friday. Medidata Solutions has a twelve month low of $59.60 and a twelve month high of $88.87. The company has a market capitalization of $4.87 billion, a PE ratio of 96.94, a price-to-earnings-growth ratio of 5.12 and a beta of 1.40. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.16.

Medidata Solutions (NASDAQ:MDSO) last announced its earnings results on Tuesday, July 24th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. Medidata Solutions had a return on equity of 11.37% and a net margin of 9.13%. The firm had revenue of $155.90 million for the quarter, compared to the consensus estimate of $155.86 million. During the same quarter in the previous year, the business earned $0.31 EPS. The company’s revenue was up 14.6% compared to the same quarter last year. analysts forecast that Medidata Solutions will post 0.79 EPS for the current fiscal year.

In related news, EVP Michael I. Otner sold 9,288 shares of the company’s stock in a transaction that occurred on Tuesday, July 24th. The stock was sold at an average price of $81.03, for a total value of $752,606.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert Taylor sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 31st. The shares were sold at an average price of $73.05, for a total value of $365,250.00. Following the completion of the transaction, the director now owns 44,036 shares in the company, valued at approximately $3,216,829.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,418 shares of company stock worth $2,860,168. 4.70% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its holdings in Medidata Solutions by 0.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 130,588 shares of the company’s stock valued at $8,202,000 after acquiring an additional 663 shares during the period. Oregon Public Employees Retirement Fund raised its holdings in Medidata Solutions by 3.0% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 22,786 shares of the company’s stock valued at $1,836,000 after acquiring an additional 666 shares during the period. Municipal Employees Retirement System of Michigan raised its holdings in Medidata Solutions by 4.0% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 18,400 shares of the company’s stock valued at $1,156,000 after acquiring an additional 710 shares during the period. Front Row Advisors LLC raised its holdings in Medidata Solutions by 6.1% during the 2nd quarter. Front Row Advisors LLC now owns 12,623 shares of the company’s stock valued at $980,000 after acquiring an additional 725 shares during the period. Finally, Polen Capital Management LLC raised its holdings in Medidata Solutions by 12.2% during the 2nd quarter. Polen Capital Management LLC now owns 7,413 shares of the company’s stock valued at $597,000 after acquiring an additional 806 shares during the period.

About Medidata Solutions

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Read More: Do You Need a Fiduciary?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply